Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Sean Janzen who wrote (1141)	1/15/1999 3:58:00 PM
From: xray	Read Replies (1) \| Respond to of 1501

IZP share price might make a surprise recovery when a substantial news release finally comes out. What they are working on is major news that most people have forgotten, just because they had a delay or two.

To: Sean Janzen who wrote (1141)	1/15/1999 10:31:00 PM
From: Harold Lehman	Read Replies (1) \| Respond to of 1501

When I checked for Inflazyme news releases on their website at about 6pm EST today I came across something called President's Update (January l999). I believe I checked for news releases in the afternoon yesterday (it could have been the day before), and I don't think it was there. You can find it by accessing: inflazyme.com and then clicking press releases. I think that it's a rather impressive document and shows that great strides have been made in developing possible drug portfolios for inflammatory diseases. They seem to be uncovering a mechanism of action, a possible new drug receptor, for their lead compound, IPL576,092, and also for a second class of compound, IPL 423, which may act by inhibiting a key inflammatory enzyme (I don't know which one, at least not yet). They also have synthesized kilogram quantities of IPL576,092, which will be enough to take them through Phase 1 clinical trials. The toxicology results should be completed on scehdule by the end of the first quarter, and if suitable, Phase 1 human studies should begin by mid-1999. Also, some not-so-miscellaneous information. Inflazyme will be expanding their studies of potential indications for IPL576 soon, including other conditions (other than asthma) with inflammatory components. Along the same vein, IPL 423 will be studied in a number of inflammatory states. There's more, esp. on the business end of things, and I encourage everyone to read the release. It's a nice piece of work. Sincerely yours, Harold